Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Preclinical · ActiveModality: In vivo CAR-T (CD7-targeted mRNA lipid nanoparticle delivery platform, CD7-tLNP)
Target CD19/BCMA
Partnerships Senlang: collaboration to develop TPST-4003 beginning with the China IIT; Senlang holds an exclusive option to negotiate a definitive license agreement for TPST-4003 in China
Status note Lead program. Combines the CD7-tLNP mRNA delivery platform with the same dual-targeting CD19/BCMA CAR architecture as TPST-2003. China IIT expected to enroll approximately 10 patients with nervous system autoimmune diseases.
TPST-2003
Phase 1 · ActiveModality: Autologous CAR-T
Target CD19/BCMA
Partnerships Erigen LLC / Factor Bioscience Inc. (asset purchase, Nov 2025): acquired all rights to TPST-2003 and three additional CAR-T programs. Cincinnati Children's Applied Gene and Cell Therapy Center (AGCTC): manufacturing partner
Status note Autologous dual-targeting CAR-T therapy. Two ongoing Phase 1 trials (REDEEM-1 in rrMM, POEMS-1 in POEMS syndrome). First potentially registrational study in rrMM planned to initiate later in 2026.
TPST-2206
Preclinical · ActiveModality: Autologous CAR-T
Target CD70
Partnerships Erigen LLC / Factor Bioscience Inc. (acquired Nov 2025)
Indications
not disclosed(Stage not disclosed)
Status note Autologous dual-targeting CAR-T; requires substantial U.S.-specific development activities before generating economic benefit.
TPST-3003
Preclinical · ActiveModality: Allogeneic CAR-T (TRAC locus gene edit inactivating the T cell receptor)
Target BCMA/CD19
Partnerships Erigen LLC / Factor Bioscience Inc. (acquired Nov 2025)
Indications
not disclosed(Stage not disclosed)
Status note Discovery-stage allogeneic BCMA/CD19 dual-targeting CAR-T.
TPST-3206
Preclinical · ActiveModality: Allogeneic CAR-T (TRAC locus gene edit inactivating the T cell receptor)
Target CD70
Partnerships Erigen LLC / Factor Bioscience Inc. (acquired Nov 2025)
Indications
not disclosed(Stage not disclosed)
Status note Discovery-stage allogeneic CD70/CD70 dual-targeting CAR-T.
Amezalpat
Stage not disclosed · Active
Target PPARα
Indications
not disclosed(Stage not disclosed)
Status note Company's most advanced product candidate; paused while the company completes its ongoing strategic review.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.